| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – |
| 13 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
On November 5, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, fr... |
| 02 Nov 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 | S-8 |
| 18 Sep 2026 |
Form 4: Nagel Robert Thorvald, Director
Granted 25,370 Stock Option |
| 18 Sep 2026 |
Form 4: Bvf Partners L P/IL, Director and 9 others
Granted 25,370 Stock Option |
| 11 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”). Dr. Nash’s resignation was not the result of any disagreement with the Company o... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
On September 9, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar (the “RMS R&D Day”). The RMS R&D Day will take place on Wednesday, September 9, 2026, f... |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | S-8 |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – |
| 11 Aug 2026 | 10-Q |
| 10 Aug 2026 |
Form 4: Ridloff Elena, Director
Granted 50,740 Stock Option |
| 10 Aug 2026 |
Form 3: Ridloff Elena, Director
No securities owned |
Loading...